Increase of PlGF (Placental Growth Factor) Level After Administration of Dydrogesterone in Pregnancy

Dewi Karlina Rusly

doi:10.18502/kme.v1i1.530

Abstract

Aim: To observe the effect of Dydrogesterone administration in pregnancy on PlGF levelMethods: This is a randomized controlled clinical trial. Study population has been divided into two groups. Group A consists of 20 women who receive only Folic acid 5 mg a day for 4 weeks time. Group B consists of 20 women who receive Dydrogesterone 2x10 mg a day and Folic acid 5 mg a day for 4 weeks. PlGF has been measured twice. First measurement was done before drug administration, while the second measurement has been done during 18th weeks of pregnancy. The changes on PlGF level before and after treatment from each group has been analyzed using SPSS 17.Results: 40 pregnant women have been recruited for this study. There are no differences based on the patient’s age, number of pregnancy and parity, gestational age and body weight between each group. The mean levels of PlGF in both groups before intervention shows no significant difference (p = 0091 or p&gt; 0.05), 40.80 pg/mL vs. 25.95 pg / mL. The mean levels of PlGF in group A after 4 weeks administration of Folic acid is 89.60 pg / mL. It shows the escalation of 48.8 pg / mL. The elevation of PlGF level in group A shows significant difference (p = 0.000 or p &lt;0.05) after 4 weeks Folic acid treatment.The mean levels of PlGF in group B after 4 weeks administration of Dydrogesterone and Folic acid is 212.15 pg / mL. It shows the escalation of 186.20 pg / mL. The elevation of PlGF level in group B shows significant difference (p = 0.000 or p &lt;0.05) after 4 weeks Dydrogesterone and Folic acid treatment.Conclusion: Dydrogesterone treatment can increase the level of PlGF.

Highlights

Selection and Peer-review under the responsibility of the ASPIRE Conference Committee.The incidence of spontaneous miscarriage occurs more than 80% at less than 12 weeks gestation recently.At least 1 of 6 couples who has successfully conceive is going to have a miscarriage
Maternal immune system response against fetal antigen can occur because fetus and placenta consist of paternal antigens
This study is trying to observe the increasing of Placental growth Factor (PlGF) (Placental Growth Factor) Level as the measurement of the placental development after administration of dydrogesterone in the pregnancy

Summary

Introduction

Selection and Peer-review under the responsibility of the ASPIRE Conference Committee. There is a popular suggestion concerning a possible link between the incidence of miscarriage with maternal immune response to fetal antigen. Maternal immune system response against fetal antigen can occur because fetus and placenta consist of paternal antigens. How to cite this article: Dewi Karlina Rusly, Kanadi Sumapradja, Rajuddin, and Kartini Hasballah, (2016) “Increase of PlGF (Placental Growth Factor) Level After Administration of Dydrogesterone in Pregnancy,” in ASPIRE Conference Proceedings, The 6th Congress of the Asia Pacific Initiative on Reproduction, KnE Medicine, pages 7–11. ASPIRE Conference Proceedings system to the fetal paternal antigens. This study is trying to observe the increasing of PlGF (Placental Growth Factor) Level as the measurement of the placental development after administration of dydrogesterone in the pregnancy

Material and Methods

Findings

Result and Discussion